CHEMED CORP

Andrea LinDell’s recent CHEMED sale shows routine insider selling amid a 0.02% price dip, yet it highlights growing insider liquidity trends and potential investor sentiment shifts for the specialty‑chemical mid‑cap.

Insider buying fuels optimism for Chemed, a dividend‑rich health‑care firm with a dual hospice‑home‑repair model and solid financials.

Chemed Corp insider sale: Grace Patrick P. sold 60 shares at $425.78, a portfolio rebalancing move amid broader executive trades and ongoing clinical trials. Explore its impact on share value and future capital strategy.

CEO sells 2,000 Chemed shares amid market dip—investors decode potential liquidity move or strategic realignment.

Chemed Corp VP buys 199 shares amid $300M buy‑back plan, signaling confidence in stock value and steady $0.60 dividend.

Insider buying at Chemed Corp signals CEO confidence: Wherley Joel L’s latest trade aligns with performance‑based PSUs, a $300 m buyback, and steady dividends, hinting at potential upside for long‑term investors.

Chemed Corp insider moves: CFO Witzeman sells and buys PSUs, boosting confidence in the $300 M buy‑back and $0.60 dividend strategy.

Chemed’s CEO buys shares amid a $300 m buy‑back and $0.60 dividend, showing confidence in the healthcare services firm’s growth and shareholder returns.

Chemed insider buy by VP Brian Judkins signals confidence amid flat share price, buy‑back program, and $0.60 quarterly dividend, boosting investor optimism.